Europe to Speed Review of RevMed Drug as Concerns Rise Over Kailera GLP-1 Pill and FDA Clears Vera Therapy
read at STAT ↗RegulatoryNeutral
European regulators said they will move more quickly to assess RevMed's investigational drug, aiming to shorten the evaluation timeline.
Separate reports highlighted that recent data from Kailera's GLP-1 oral pill have prompted safety and efficacy questions among analysts.
The U.S. Food and Drug Administration announced clearance for Vera's autoimmune therapy, marking a regulatory milestone for the company.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Europe will accelerate its review of RevMed’s drug”
read at STAT ↗506 words · retrieved Jul 8
comments(0)
5-min edit window · permanent after that